GAMMAGARD LIQUID ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
65	原発性免疫不全症候群	2

65. 原発性免疫不全症候群

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03277313 (ClinicalTrials.gov)	September 25, 2017	7/9/2017	Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric ...	Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric ...	Primary Immunodeficiency Diseases (PID)	Biological: HYQVIA;Biological: GAMMAGARD LIQUID	Baxalta now part of Shire	Baxalta Innovations GmbH, now part of Shire	Completed	2 Years	15 Years	All	44	Phase 3	United States
2	NCT00814320 (ClinicalTrials.gov)	December 18, 2008	23/12/2008	Gammagard Liquid and rHuPH20 in PID	Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (G ...	Primary Immunodeficiency Diseases (PID)	Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)	Baxalta now part of Shire	NULL	Completed	2 Years	N/A	All	89	Phase 3	United States;Canada

First Previous1Next Last